126 active
/
354 total (since 2015)
58
Phase 1 Active
146 total
68
Phase 2 Active
182 total
28
Phase 3 Active
79 total
9
Phase 4 Active
22 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Amylyx Pharmaceuticals Inc. 3 4 0
Biogen 2 5 4
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 2 0 0
AB Science 2 0 0
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. 2 0 0
Spinogenix 1 1 1
Novartis 1 1 1
Clene Nanomedicine 1 1 1
Ferrer Internacional S.A. 1 1 1
MediciNova 1 1 0
QurAlis Corporation 1 1 0
UCB Biopharma SRL 1 1 0
Brainstorm-Cell Therapeutics 1 1 0
Corestemchemon, Inc. 1 1 0
Corcept Therapeutics 1 0 0
NCT04302870 RECRUITING
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
University of Edinburgh n=1,150
NCT07325591 NOT YET RECRUITING
Efficacy and Safety of Tazbentetol in ALS Participants
Spinogenix n=430
NCT07322003 RECRUITING
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia n=500
NCT04768972 ACTIVE NOT RECRUITING
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Ionis Pharmaceuticals, Inc. n=89
NCT07410806 ENROLLING BY INVITATION
HEALEY ALS Platform Trial - Regimen I NUZ-001
Merit E. Cudkowicz, MD n=160
NCT07226700 RECRUITING
Suzetrigine in Total Hip Arthroplasty
Hospital for Special Surgery, New York n=210
NCT07321860 NOT YET RECRUITING
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Gipfel Life Sciences GmbH n=60
NCT07174492 NOT YET RECRUITING
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
AB Science n=412
NCT06126315 RECRUITING
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Mario Negri Institute for Pharmacological Research n=246
NCT04057898 ACTIVE NOT RECRUITING
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
MediciNova n=234
NCT03127267 RECRUITING
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
AB Science n=495
NCT07147972 NOT YET RECRUITING
Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine
Fayoum University n=100
NCT05206513 ACTIVE NOT RECRUITING
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Neurocrine Biosciences n=86
NCT07082192 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Shanghai Zhimeng Biopharma, Inc. n=240
NCT06719947 NOT YET RECRUITING
HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Universidade Federal do Rio Grande do Norte n=80
NCT06008249 RECRUITING
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
Stichting TRICALS Foundation n=171
NCT06536751 RECRUITING
Therapeutic Photobiomodulation and Tretament of Spasticity
University of Nove de Julho n=28
NCT06973629 NOT YET RECRUITING
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Brainstorm-Cell Therapeutics n=200
NCT06872736 RECRUITING
Wereables for Upper Limb Functionality in Hemiparesis
Universidade da Coruña n=40
NCT04856982 ACTIVE NOT RECRUITING
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
Biogen n=158
NCT03198702 RECRUITING
Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy
University Hospital, Brest n=62
NCT04745299 ACTIVE NOT RECRUITING
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS
Corestemchemon, Inc. n=115
NCT06122662 ACTIVE NOT RECRUITING
AMX0035 and Progressive Supranuclear Palsy
Amylyx Pharmaceuticals Inc. n=110
NCT05021536 ACTIVE NOT RECRUITING
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Amylyx Pharmaceuticals Inc. n=664
NCT06391645 NOT YET RECRUITING
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
Beijing Tiantan Hospital n=60
NCT03676439 RECRUITING
Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy
Sociedad Argenttina de Neuromodulación n=20
NCT03616067 TERMINATED
Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy
Hospices Civils de Lyon n=23
NCT05568615 COMPLETED
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
Tanabe Pharma Corporation n=15
NCT04569084 TERMINATED
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
Tanabe Pharma America, Inc. n=384
NCT05151471 TERMINATED
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
Tanabe Pharma America, Inc. n=202
NCT04165824 COMPLETED
Safety Study of Oral Edaravone Administered in Subjects With ALS
Tanabe Pharma America, Inc. n=185
NCT04577404 COMPLETED
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Tanabe Pharma America, Inc. n=124
NCT03293069 COMPLETED
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
University Hospital, Lille n=372
NCT05740813 COMPLETED
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Merit E. Cudkowicz, MD n=310
NCT05193994 TERMINATED
Triumeq in Amyotrophic Lateral Sclerosis
Macquarie University, Australia n=419
NCT06658977 TERMINATED
RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
Macquarie University, Australia n=12
NCT05136885 COMPLETED
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
Merit E. Cudkowicz, MD n=161
NCT03548311 COMPLETED
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS
Eisai Co., Ltd. n=130
NCT05178810 COMPLETED
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A. n=313
NCT05866926 TERMINATED
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A. n=201
NCT05619783 COMPLETED
Extension Study Evaluating The Safety And Tolerability of AMX0035
Amylyx Pharmaceuticals Inc. n=352
NCT04944784 TERMINATED
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Cytokinetics n=489
NCT03216837 COMPLETED
Stimulation for Perinatal Stroke Optimizing Recovery Trajectories
University of Calgary n=89
NCT03280056 COMPLETED
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Brainstorm-Cell Therapeutics n=196
NCT03746522 COMPLETED
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Rhythm Pharmaceuticals, Inc. n=52
NCT04193527 COMPLETED
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
GE Healthcare n=172
NCT03836716 TERMINATED
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
ZevraDenmark n=120
NCT04615923 COMPLETED
HEALEY ALS Platform Trial - Regimen D Pridopidine
Merit E. Cudkowicz, MD n=163
NCT02623699 COMPLETED
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Biogen n=176
NCT02839642 COMPLETED
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
Assistance Publique Hopitaux De Marseille n=106
NCT04436510 COMPLETED
HEALEY ALS Platform Trial - Regimen B Verdiperstat
Merit E. Cudkowicz, MD n=167
NCT04516096 COMPLETED
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
Amylyx Pharmaceuticals Inc. n=28
NCT03315832 WITHDRAWN
Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study
University Hospital, Limoges
NCT03948178 TERMINATED
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
Orion Corporation, Orion Pharma n=227
NCT05277376 COMPLETED
Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial
DSM Nutritional Products, Inc. n=162
NCT04248465 TERMINATED
An Efficacy and Safety Study of Ravulizumab in ALS Participants
Alexion Pharmaceuticals, Inc. n=382
NCT03469999 COMPLETED
Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
Columbia University n=12
NCT03505021 COMPLETED
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
Orion Corporation, Orion Pharma n=496
NCT02270736 COMPLETED
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
Merz Pharmaceuticals GmbH n=256
NCT03184584 TERMINATED
Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Liminal BioSciences Ltd. n=10
NCT03068754 TERMINATED
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)
Mallinckrodt n=143
NCT02496767 COMPLETED
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
Cytokinetics n=744
NCT03302871 COMPLETED
Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A
Kocaeli University n=40
NCT03472261 COMPLETED
Integrated Management of Pronation Deformity in Cerebral Palsy
Kocaeli University n=35
NCT02839785 TERMINATED
Analgesia and Physiotherapy in Children With Cerebral Palsy (ANTALKINECP)
University Hospital, Brest n=3
NCT03342118 COMPLETED
Effect of Oral Phloroglucin (Flospan®) as Premedication of Non-sedative Diagnostic Esophagogastroduodenoscopy
Keimyung University Dongsan Medical Center n=140
NCT02591004 COMPLETED
Calcium Channel Blockers Compared to Magnesium Sulfate in Fetal Cerebral Blood Flow
Kasr El Aini Hospital n=130
Data: ClinicalTrials.gov